Janssen COVID-19 vaccine

Janssen COVID-19 Vaccine

File:Janssen COVID-19 vaccine vial.jpg

A vial of the Janssen COVID-19 vaccine

The Janssen COVID-19 Vaccine is a COVID-19 vaccine developed by Janssen Pharmaceutica, a Belgium-based division of Johnson & Johnson. It is also known as the Johnson & Johnson COVID-19 vaccine. The vaccine is based on a viral vector technology, using a human adenovirus to express the spike protein found on the surface of the SARS-CoV-2 virus that causes COVID-19.

Development and Authorization

The development of the Janssen COVID-19 vaccine began in early 2020, following the outbreak of the COVID-19 pandemic. The vaccine was authorized for emergency use by the U.S. Food and Drug Administration (FDA) on February 27, 2021, and by the European Medicines Agency (EMA) on March 11, 2021.

Efficacy and Safety

Clinical trials have shown that the Janssen COVID-19 vaccine has an efficacy rate of approximately 66% in preventing moderate to severe COVID-19 infection. The vaccine has been found to be safe and well-tolerated in the majority of recipients, with side effects generally mild and short-lived.

Administration and Storage

The Janssen COVID-19 vaccine is administered as a single dose, unlike most other COVID-19 vaccines which require two doses. This makes it easier to administer and distribute, particularly in areas where healthcare resources are limited. The vaccine can be stored at standard refrigerator temperatures for up to three months, making it more practical for use in many parts of the world.

See Also

• COVID-19 pandemic
• COVID-19 vaccine
• Johnson & Johnson
• Janssen Pharmaceutica